NCT02332941View on ClinicalTrials.gov

Treatment -Resistant Neovascular Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Macular Degeneration
Interventions
DRUG

Rituximab

The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02332941 - Treatment -Resistant Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter